Don’t overlook the most important metric for Johnson & Johnson’s Covid-19 vaccine ...Middle East

Quartz - Economy
Don’t overlook the most important metric for Johnson & Johnson’s Covid-19 vaccine
When Janssen, a subsidiary of Johnson & Johnson, announced that its Covid-19 vaccine could prevent 66% of symptomatic Covid-19 cases, the response was lukewarm. The first Covid-19 vaccines have set the bar high. Both mRNA vaccines from Pfizer-BioNTech and Moderna showed they could stop over 90% of symptomatic Covid-19 cases in their late-stage clinical trials.But Janssen’s vaccine shines by another metric: reducing the severity of the disease, potentially freeing up hospital beds. One of the most dangerous effects of Covid-19 is that it sends about 2% of patients to intensive care units in hospitals. The more Covid-19 patients lying in hospital beds, the more likely overwhelmed hospitals wi

Hence then, the article about don t overlook the most important metric for johnson johnson s covid 19 vaccine was published today ( ) and is available on Quartz ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Don’t overlook the most important metric for Johnson & Johnson’s Covid-19 vaccine )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in Economy


Latest News